Richards R, Simpson S F, Renwick A G, Holgate S T
Medicine I, Southampton General Hospital, England.
Eur Respir J. 1988 Dec;1(10):896-901.
We have investigated whether the inspiratory flow at which sodium cromoglycate (SCG) is inhaled influences the efficacy of SCG. Seven atopic asthmatic subjects (age 25 +/- 2 yrs) inhaled dry powder SCG from a Spinhaler on separate occasions at three flow rates, maximum (V1), 100 l.min-1 (V2), and 50 l.min-1 (V3), or placebo, according to a double-blind structured study. Thirty minutes after administration a bronchial provocation test was performed with adenosine 5'-monophosphate (AMP). Blood samples for measurement of plasma SCG concentration were taken and the area under the plasma concentration-time curve (AUC) calculated for each flow rate. Both inspiratory flow rate and AUC correlated significantly with the degree of protection afforded against AMP-induced bronchoconstriction (r = 0.73, p less than 0.001; r = 0.66, p less than 0.001). These findings indicate that the flow rate used to inhale powdered SCG is a major factor in determining the protective efficacy of this drug against bronchial challenge and therefore has important clinical implications.
我们研究了吸入色甘酸钠（SCG）时的吸气流量是否会影响SCG的疗效。根据一项双盲结构化研究，7名特应性哮喘患者（年龄25±2岁）在不同时间分别以三种流量从Spinhaler吸入干粉状SCG，即最大流量（V1）、100升/分钟（V2）和50升/分钟（V3），或吸入安慰剂。给药30分钟后，用5'-单磷酸腺苷（AMP）进行支气管激发试验。采集血样以测量血浆SCG浓度，并计算每种流量下血浆浓度-时间曲线下面积（AUC）。吸气流量和AUC均与针对AMP诱导的支气管收缩的保护程度显著相关（r = 0.73，p<0.001；r = 0.66，p<0.001）。这些发现表明，用于吸入粉状SCG的流量是决定该药物对支气管激发的保护疗效的主要因素，因此具有重要的临床意义。
